CBM: Cambrex Corporation Instablogs

Quote & Headlines Market Currents StockTalk

All
| Earnings
| Dividends
| M&A
| On the move

Friday, May 3, 8:15 AM Cambrex (CBM): Q1 EPS of $0.37 beats by $0.15. Net Revenue of $74.8M (+5.7% Y/Y). (PR) Comment! [Earnings, Breaking News, Healthcare]
Thursday, February 14, 10:59 AM Cambrex (CBM -1%) and Dow Chemical (DOW -0.9%) sign an agreement for CBM to contract manufacture DOW's Hydroxypropyl Methylcellulose Acetate Succinate for use in drug solubility enhancement. The agreement is the final realization of a solubilization partnership that Dow and Bend Research announced in October 2012. Construction has already begun on the new operational facility at Cambrex Karlskoga with commercial product availability set for year-end 2013. Comment! [Healthcare]
Thursday, February 7, 2:49 PM Cambrex Corp (CBM +12.3%) moves up after reporting Q4 earnings that crushed the Street consensus. Sales rose 4.8% over the prior year quarter to $69.9M, beating forecasts by about $1.93M. Looking forward, the company expects 8% to 12% sales growth in FY13, which equates to around $298.5M to $304M this year. The Street is at $298.1M. Comment! [Earnings, On the Move, Healthcare]
Wednesday, February 6, 5:42 PM Cambrex (CBM): Q4 EPS of $1.44 (incl. charges). Revenue of $69.9M (+3.6% Y/Y) beats by $1.9M. (PR) Comment! [Earnings, Breaking News, Healthcare]
Tuesday, November 6, 2012, 12:45 PM Midday top 10 gainers: NVGN +89%. FN +25%. ENOC +19%. ROSG +19%. WTW +18%. CSC +17%. ODP +17%. JIVE +16%. AOL +16%. ACAD +15%. Midday top 10 Losers: THQI -48%. SREV -37%. SYPR -35%. MKTG -30%. VVUS -23%. CDE -22%. CBM -22%. Z -19%. MMYT -18%. ANTH -17%. Comment!
Monday, November 5, 2012, 5:41 PM Cambrex (CBM): Q3 EPS of $0.07 misses by $0.05. Revenue of $59.8M (+0.1% Y/Y) in-line. (PR) Comment! [Earnings, Healthcare]
Wednesday, August 1, 2012, 5:33 PM Cambrex (CBM): Q2 EPS of $0.33 beats by $0.12. Revenue of $77.1M (+4% Y/Y) beats by $6M. (PR) Comment! [Earnings, Healthcare]
Friday, May 4, 2012, 12:18 PM Life Sciences research firm Cambrex (CBM +13%) pops after its Q1 results easily topped Street estimates late yesterday. Overall revenue rose 14% Y/Y on higher sales of controlled substances and generic active pharmaceutical ingredients. The company also raises sales projections for FY12, now expecting sales to increase between 2% - 6% year-over-year. Comment! [Healthcare, Earnings, On the Move]
Thursday, May 3, 2012, 5:47 PM Cambrex (CBM): Q1 EPS of $0.24 beats by $0.10. Revenue of $70.6M (+14.4% Y/Y) beats by $6M. (PR) Comment! [Earnings, Healthcare]
Monday, February 6, 2012, 6:39 PM More on Cambrex (CBM): Q4 beats on revenue but misses on a per share basis, as income from continuing operations came in at $3M, or $0.10 per share, down from $0.18 per share during the same period in 2010. The company also expects 2012 sales should rise between 2% - 6% over 2011 levels, in line with analyst expectations. Shares -2.4% AH. Comment! [On the Move, Earnings]
Monday, February 6, 2012, 4:56 PM Cambrex (CBM): Q4 EPS of $0.10 misses by $0.02. Revenue of $67.1M (+4.1% Y/Y) beats by $2.2M. Shares -2.6% AH. (PR) Comment! [Earnings, Healthcare, On the Move]
Wednesday, August 3, 2011, 1:22 PM Cambrex (CBM +25.6%) shares are soaring the day after the maker of pharmaceutical ingredients reported better-than-expected Q2 earnings and revenue. Cambrex said sales rose 17.6% Y/Y to $65.7M; excluding the impact of a weak U.S. dollar, sales rose 6.9%. Comment! [Healthcare, Earnings, On the Move]

CBM Cambrex Corporation

CBM

Cambrex Corporation